drugset / Trial / NCT00275301

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

NCT00275301

NaSingle-groupOpen-labelTreatment

Summary

The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.

Timeline

Start
2005-12
Primary completion
2008-04
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 7.5 mg Oral